Hematologic Malignancy
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CI-CAN-00000765Explore in graph →
Hematologic298 active trials6 approved drugs47 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000765Explore in graph →
Clinical trials
1,406 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (273)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00536341 | Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 64 | SCRI Development Innovations, LLCOTHER | 1 | Jan 16, 2017 | clinicaltrials |
| NCT01681563 | Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 47 | Niguarda HospitalOTHER | 1 | Dec 28, 2016 | clinicaltrials |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | terminated | Phase 2 | 7 | University of RochesterOTHER | 1 | Dec 22, 2016 | clinicaltrials |
| NCT01600053 | Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia | terminated | Phase 2 | 11 | Thomas KippsOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT02892695 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT00683046 | T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 2 | 204 | University of ChicagoOTHER | 1 | Nov 22, 2016 | clinicaltrials |
| NCT01459211 | Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)(LenD) | completed | Phase 2 | 12 | University College, LondonOTHER | 1 | Nov 8, 2016 | clinicaltrials |
| NCT00254163 | Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients | completed | Phase 3 | 184 | US Oncology ResearchINDUSTRY | 1 | Nov 3, 2016 | clinicaltrials |
| NCT01087151 | A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 118 | Genentech, Inc.INDUSTRY | 12 | Nov 2, 2016 | clinicaltrials |
| NCT01395615 | An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia | completed | — | 34 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01072240 | An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia | completed | — | 92 | Hoffmann-La RocheINDUSTRY | 1 | Nov 1, 2016 | clinicaltrials |
| NCT02819583 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Oct 25, 2016 | clinicaltrials |
| NCT00098371 | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | terminated | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT00714103 | 8-Chloro-Adenosine in Chronic Lymphocytic Leukemia | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 13, 2016 | clinicaltrials |
| NCT00147901 | Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) | completed | Phase 2 | 61 | German CLL Study GroupOTHER | 1 | Oct 3, 2016 | clinicaltrials |
| NCT00276809 | Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | completed | Phase 2 | 30 | German CLL Study GroupOTHER | 1 | Sep 26, 2016 | clinicaltrials |
| NCT00416910 | Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | terminated | Phase 3 | 83 | German CLL Study GroupOTHER | 0 | Sep 26, 2016 | clinicaltrials |
| NCT02015208 | Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 13 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 26, 2016 | clinicaltrials |
| NCT01113632 | Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 77 | SCRI Development Innovations, LLCOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT01809847 | Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation | completed | Phase 2 | 20 | Technische Universität DresdenOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01527838 | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | completed | Phase 1 | 10 | Fate TherapeuticsINDUSTRY | 1 | Sep 12, 2016 | clinicaltrials |
| NCT00771056 | Hydroxychloroquine in Untreated B-CLL Patients | terminated | Phase 2 | 23 | Northwell HealthOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT02456350 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT00046683 | Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia | completed | Phase 3 | 284 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jul 28, 2016 | clinicaltrials |
| NCT00533923 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 18, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT02046928 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 5 | Ångstrom PharmaceuticalsINDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02828774 | Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia | unknown | — | 30 | Assuta Medical CenterOTHER | 0 | Jul 12, 2016 | clinicaltrials |
| NCT01871675 | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | completed | Phase 1 | 48 | SCRI Development Innovations, LLCOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT02110394 | Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia(NORMA) | completed | — | 190 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jul 6, 2016 | clinicaltrials |
| NCT01649791 | Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia | terminated | N/A | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT02315118 | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 18 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02273856 | Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)(NADIR) | terminated | — | 25 | Astellas Pharma International B.V.INDUSTRY | 7 | Jun 21, 2016 | clinicaltrials |
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) | terminated | — | 88 | Stanford UniversityOTHER | 1 | Jun 16, 2016 | clinicaltrials |
| NCT00751296 | Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)(Rev-CLL) | terminated | Phase 2 | 27 | University Health Network, TorontoOTHER | 1 | Jun 16, 2016 | clinicaltrials |
| NCT00543114 | Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL | terminated | Phase 1 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | May 27, 2016 | clinicaltrials |
| NCT01703364 | Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL | completed | Phase 1 / Phase 2 | 12 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2016 | clinicaltrials |
| NCT00330252 | Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL | completed | Phase 1 | 29 | Dana-Farber Cancer InstituteOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT01212380 | Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) | completed | Phase 1 | 21 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 9, 2016 | clinicaltrials |
| NCT02533401 | A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 34 | Hoffmann-La RocheINDUSTRY | 2 | May 2, 2016 | clinicaltrials |
| NCT02507479 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01744626 | Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 1 | 40 | Celgene CorporationINDUSTRY | 2 | Apr 19, 2016 | clinicaltrials |
| NCT00532129 | A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia. | completed | Phase 2 | 100 | Hoffmann-La RocheINDUSTRY | 1 | Apr 6, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jan 16, 2017source: clinicaltrials